A Study of Bumetanide for the Treatment of Autism Spectrum Disorders
A Study of Bumetanide for the Treatment of Children With Autism Spectrum Disorder：a Randomized Double-blind Placebo-controlled Trial
Sponsor: Shanghai Jiao Tong University School of Medicine
This PHASE2 trial investigates Autism Spectrum Disorder and is currently completed. Shanghai Jiao Tong University School of Medicine leads this study, which shows 7 recorded versions since 2017 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Mar 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Mar 2021 [monthly]
Completed PHASE2
-
Mar 2020 — Jan 2021 [monthly]
Completed PHASE2
Status: Unknown Status → Completed
▶ Show 2 earlier versions
-
May 2019 — Mar 2020 [monthly]
Unknown Status PHASE2
Status: Not Yet Recruiting → Unknown Status
-
Jun 2017 — May 2019 [monthly]
Not Yet Recruiting PHASE2
First recorded
May 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Shanghai Jiao Tong University School of Medicine
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Shanghai, China